Ftse Mib
34.460,52
0,00%
DAX
18.680,20
-0,25%
S&P 500
5.307,01
-0,27%
NASDAQ
16.801,54
-0,18%
Bitcoin
69.364,34
0,38%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Silence Therapeutics PLC (SLN) Silence Therapeutics PLC (SLN) Notizie

SLN

Silence Therapeutics (SLN)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SLN
DataOraFonteTitoloSimboloCompagnia
17/05/202423:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SLNSilence Therapeutics PLC
16/05/202414:30Business WireSilence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline ProgressNASDAQ:SLNSilence Therapeutics PLC
14/05/202422:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SLNSilence Therapeutics PLC
08/05/202423:14Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:SLNSilence Therapeutics PLC
30/04/202414:30Business WireSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceNASDAQ:SLNSilence Therapeutics PLC
29/04/202414:30Business WireSilence Therapeutics Announces Retirement of Alistair Gray from Board of DirectorsNASDAQ:SLNSilence Therapeutics PLC
08/04/202417:48Business WireSilence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
13/03/202412:05Business WireSilence Therapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsNASDAQ:SLNSilence Therapeutics PLC
13/03/202412:03IH Market NewsMixed Futures Amidst Quiet Economic Schedule; Oil Prices ClimbNASDAQ:SLNSilence Therapeutics PLC
13/03/202412:00Business WireSilence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)NASDAQ:SLNSilence Therapeutics PLC
28/02/202414:00Business WireSilence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024NASDAQ:SLNSilence Therapeutics PLC
23/02/202414:00Business WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 TrialNASDAQ:SLNSilence Therapeutics PLC
14/02/202415:54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SLNSilence Therapeutics PLC
05/02/202414:00Business WireSilence Therapeutics Announces Oversubscribed $120 Million Private PlacementNASDAQ:SLNSilence Therapeutics PLC
31/01/202413:00Business WireSilence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:SLNSilence Therapeutics PLC
01/12/202313:00Business WireSilence Therapeutics Strengthens Executive Leadership Team with Key AppointmentsNASDAQ:SLNSilence Therapeutics PLC
14/11/202313:00Business WireSilence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial ResultsNASDAQ:SLNSilence Therapeutics PLC
08/11/202313:00Business WireSilence Therapeutics to Present at Jefferies London Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
01/11/202312:00Business WireSilence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular DiseaseNASDAQ:SLNSilence Therapeutics PLC
26/09/202313:00Business WireSilence Therapeutics to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines ConferenceNASDAQ:SLNSilence Therapeutics PLC
06/09/202313:00Business WireSilence Therapeutics to Participate in September Investor ConferencesNASDAQ:SLNSilence Therapeutics PLC
29/08/202322:01Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:SLNSilence Therapeutics PLC
16/08/202313:00Business WireSilence Therapeutics Reports Second Quarter 2023 ResultsNASDAQ:SLNSilence Therapeutics PLC
01/08/202322:31Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SLNSilence Therapeutics PLC
11/07/202313:00Business WireSilence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma CollaborationNASDAQ:SLNSilence Therapeutics PLC
31/05/202313:00Business WireSilence Therapeutics to Present at the Jefferies Healthcare ConferenceNASDAQ:SLNSilence Therapeutics PLC
16/05/202322:02Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:SLNSilence Therapeutics PLC
16/05/202322:00Business WireSilence Therapeutics Reports First Quarter 2023 ResultsNASDAQ:SLNSilence Therapeutics PLC
04/05/202313:00Business WireSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca CollaborationNASDAQ:SLNSilence Therapeutics PLC
01/05/202313:00Business WireSilence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease EventsNASDAQ:SLNSilence Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SLN

La tua Cronologia

USOTC
MHLGS
370 Markets (CE)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network